Tag - AAPG

Feature

Ascentage reviving programmed cell death with novel approach to hematologic malignancies

Ascentage Pharma (NASDAQ: AAPG; HKEX: 6855) is advancing its proprietary drug discovery platform of first- and best-in-class small molecule therapies to address unmet medical needs in cancers and other diseases.

August 12, 2025

Developments

China’s NMPA approves Ascentage’s lisaftoclax for CLL/SLL

Ascentage Pharma (NASDAQ: AAPG; HKEX: 6855) has announced that China’s National Medical Products Administration (NMPA) has approved its proprietary novel Bcl-2 selective inhibitor lisaftoclax (APG-2575) for the...

July 10, 2025

Executive Moves

New CFO and SVP join Ascentage

Ascentage Pharma (NASDAQ: AAPG; HKEX: 6855) has announced the appointment of Veet Misra, PhD, as chief financial officer (CFO), and Eric Huang as senior vice president (SVP) of global corporate development and...

July 8, 2025

Tag - AAPG

Ascentage reviving programmed cell death with novel approach to hematologic malignancies

China’s NMPA approves Ascentage’s lisaftoclax for CLL/SLL

New CFO and SVP join Ascentage

Subscribe